Caribou Biosciences Q3 2026 Results: Net Loss of $26.6M, Loss Narrows
Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.
- Key figure
- Net loss $26.6M